Lansoprazole sulfone
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 591361

CAS#: 131926-99-3

Description: Lansoprazole sulfone is a metabolite of the gastric pump inhibitor Lansoprazole.


Price and Availability

Size
Price

10mg
USD 430
Size
Price

Size
Price

Lansoprazole sulfone, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 200mg may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 591361
Name: Lansoprazole sulfone
CAS#: 131926-99-3
Chemical Formula: C16H14F3N3O3S
Exact Mass: 385.0708
Molecular Weight: 385.36
Elemental Analysis: C, 49.87; H, 3.66; F, 14.79; N, 10.90; O, 12.46; S, 8.32


Synonym: Lansoprazole sulfone; AG-1813; AG 1813; AG1813

IUPAC/Chemical Name: 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfonyl)-

InChi Key: TVMJMCGRSSSSDJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H14F3N3O3S/c1-10-13(20-7-6-14(10)25-9-16(17,18)19)8-26(23,24)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

SMILES Code: O=S(C1=NC2=CC=CC=C2N1)(CC3=NC=CC(OCC(F)(F)F)=C3C)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Zhang D, Zhang Y, Liu M, Wang X, Yang M, Han J, Liu H. Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2013 Sep;38(3):209-15. doi: 10.1007/s13318-012-0115-8. Epub 2012 Dec 11. PubMed PMID: 23229306.

2: Zhang D, Yang M, Liu M, Zhang Y, Wang X, Xiao X, Liu H. Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects. Xenobiotica. 2012 Nov;42(11):1156-62. doi: 10.3109/00498254.2012.687119. Epub 2012 May 21. PubMed PMID: 22612620.

3: Zhang D, Wang X, Yang M, Wang G, Liu H. Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects. Xenobiotica. 2011 Jun;41(6):511-7. doi: 10.3109/00498254.2011.559556. Epub 2011 Apr 27. Erratum in: Xenobiotica. 2011 Sep;41(9):836. PubMed PMID: 21521077.

4: Xu HR, Chen WL, Li XN, Chu NN. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects. Pharm Biol. 2010 Aug;48(8):947-52. doi: 10.3109/13880200903300220. PubMed PMID: 20673183.

5: Yanagida Y, Watanabe M, Takeba Y, Kumai T, Matsumoto N, Hayashi M, Suzuki S, Kinoshita Y, Kobayashi S. Potential of lansoprazole as a novel probe for cytochrome P450 3A activity by measuring lansoprazole sulfone in human liver microsomes. Biol Pharm Bull. 2009 Aug;32(8):1422-6. PubMed PMID: 19652384.

6: Song M, Gao X, Hang TJ, Wen AD. Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects. Curr Ther Res Clin Exp. 2009 Jun;70(3):228-39. doi: 10.1016/j.curtheres.2009.05.002. PubMed PMID: 24683233; PubMed Central PMCID: PMC3967358.

7: Song M, Gao X, Hang T, Wen A. Simultaneous determination of lansoprazole and its metabolites 5'-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS/MS: application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal. 2008 Dec 1;48(4):1181-6. doi: 10.1016/j.jpba.2008.08.034. Epub 2008 Sep 9. PubMed PMID: 18945568.

8: Miura M, Kagaya H, Tada H, Uno T, Yasui-Furukori N, Tateishi T, Suzuki T. Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole. Xenobiotica. 2006 Jan;36(1):95-102. PubMed PMID: 16507515.

9: Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol. 2005 Jul;60(1):61-8. PubMed PMID: 15963095; PubMed Central PMCID: PMC1884909.

10: Saito M, Yasui-Furukori N, Uno T, Takahata T, Sugawara K, Munakata A, Tateishi T. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005 Mar;59(3):302-9. PubMed PMID: 15752376; PubMed Central PMCID: PMC1884793.

11: Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T. Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 25;816(1-2):309-14. PubMed PMID: 15664363.

12: Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004 Nov;44(11):1223-9. PubMed PMID: 15496639.

13: Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol. 2004 Nov;60(9):623-8. Epub 2004 Sep 23. PubMed PMID: 15448955.

14: Miura M, Tada H, Suzuki T. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 May 25;804(2):389-95. PubMed PMID: 15081934.

15: Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem. 2003 Mar 28;278(13):10993-1001. Epub 2003 Jan 15. PubMed PMID: 12529378.

16: Ushiama H, Echizen H, Nachi S, Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther. 2002 Jul;72(1):33-43. PubMed PMID: 12152002.

17: Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol. 2001 Dec;57(10):709-15. PubMed PMID: 11829200.

18: Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes. J Chromatogr B Biomed Sci Appl. 2001 Jun 5;757(1):127-33. PubMed PMID: 11419737.

19: Masa K, Hamada A, Arimori K, Fujii J, Nakano M. Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs. Biol Pharm Bull. 2001 Mar;24(3):274-7. PubMed PMID: 11256484.

20: Masa K, Arimori K, Nakayama T, Miyamoto S, Fujii J, Nakano M. Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs. Biol Pharm Bull. 1999 May;22(5):504-9. PubMed PMID: 10375172.